Department of Biosynthesis, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai, China.
Inflammation. 2010 Jun;33(3):166-72. doi: 10.1007/s10753-009-9170-y.
Reactive oxygen species (ROS) are believed to play a key role in the induction of lung damage caused by pneumonia and therapeutic agents that could effectively scavenge ROS may prevent or reduce the deleterious effects of influenza-induced pneumonia. In this study, we first demonstrated that human catalase could attenuate acute oxidative injury in lung tissues following influenza-induced pneumonia. Mice were infected with influenza virus H1N1 (FM1 strain) and treated with recombinant human catalase (50,000 U/kg) by inhalation. The survival time and survival rates of H1N1 induced pneumonia mice were increased by treatment with recombinant human catalase. Protective efficacy of catalase was also observed in lung histology, anti-oxidant parameters, pulmonary pathology and influenza viral titer in lungs in mice. These observations were associated with increased serum superoxide and hydroxyl radical anion scavenging capacities. This study strongly indicated that recombinant catalase might be a potential therapy for H1N1 influenza-induced pneumonia.
活性氧（ROS）被认为在肺炎引起的肺损伤诱导中起关键作用，能够有效清除 ROS 的治疗剂可能预防或减轻流感引起的肺炎的有害影响。在这项研究中，我们首先证明人过氧化氢酶可以减轻流感病毒诱导的肺炎后肺组织的急性氧化损伤。用流感病毒 H1N1（FM1 株）感染小鼠，并通过吸入给予重组人过氧化氢酶（50000 U/kg）。用重组人过氧化氢酶治疗可增加 H1N1 诱导肺炎小鼠的存活时间和存活率。在肺组织学、抗氧化参数、肺病理学和肺中流感病毒滴度方面也观察到了过氧化氢酶的保护作用。这些观察结果与血清中超氧阴离子和羟自由基清除能力的增加有关。这项研究强烈表明，重组过氧化氢酶可能是治疗 H1N1 流感引起的肺炎的一种潜在疗法。
